摘要
目的探讨藤黄酸联合舒尼替尼抑制肾癌细胞增殖的作用。方法单独或联合应用藤黄酸和舒尼替尼分别作用肾癌786-0细胞株,采用MTT比色法、流式细胞技术分别检测细胞活力和周期变化,Western blot检测与细胞周期及血管形成相关的蛋白变化。构建786-0细胞株裸鼠移植瘤模型,以藤黄酸单独或联合舒尼替尼治疗裸鼠移植瘤,测量移植瘤生长情况,免疫组织化学法检测移植瘤生长和血管生长情况。结果联合应用藤黄酸与舒尼替尼比单药组更显著抑制细胞增殖(P<0.05),并且更多的细胞周期聚集于sub-G1期(P<0.05),Western blot显示其与单药组比较Bcl-2表达显著减少,P21表达显著增加,VEGF显著减少(P<0.05)。体内实验显示:联合用药组比单药组更能显著抑制裸鼠移植瘤及血管的形成(P<0.05)。结论联合应用藤黄酸和舒尼替尼治疗肾癌比单独用药能够更显著抑制肿瘤形成。
the growth of renal Objective To determine the inhibitory effect of garcinia acid combined with sunitinib on carcinoma cells. Methods Garcinia acid alone （0 to 8 Ixmol/L） or in combination with sunitinib （0 to 8 μmol/L） were used to treat 786-0 cells. MTI assay and flow cytometry were used to detect changes in cell viability and cycle. Western blotting was used to detect the expression of proteins related to cell cycle and angiogenesis. Xenograft model of 786-0 cells was constructed after treated by garcinia acid alone or in combination with sunitinib. Tumor growth and blood vessel growth in the nude mice were observed and measured by immunohistochemical assay. Results The combination of garcinia acid and sunitinib showed more significantly inhibitory effect on cell proliferation, and induced more cells arrested at sub-G1 phase than monotherapy treatment （P 〈 0.05 ）. Western blotting showed that the cell cycle regulatory protein Bcl-2 was significantly reduced, P21 expression was significantly increased, and VEGF expression was significantly decreased in combined treatment group than in the monotherapy group （ P 〈 0.05 ）. Xenograft growth and vascular formation were significantly inhibited in the combined treatment group than a single drug group in renal cell carcinoma transplanted nude mice （P 〈 0.05 ）. Conclusion The combination treatment of garcinia acid and sunitinib significantly inhibits kidney tumor formation than the individual drug alone.
出处
《第三军医大学学报》
CAS
CSCD
北大核心
2014年第7期687-690,共4页
Journal of Third Military Medical University
关键词
藤黄酸
舒尼替尼
肾癌
garcinia acid
sunitinib
renal cell carcinoma
